Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More
Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More
Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More
Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More
Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. This… Read More
